---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-22-000064"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:11:52.758882+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio Q3 net loss $33.5M ($1.18/sh); cash $590.5M; alopecia areata data Q1 2023

## Summary
- Net loss $33.5M (Q3 2022) vs $6.7M (Q3 2021); loss/share $1.18 vs $0.24.
- Cash & investments $590.5M as of Sep 30, 2022, down $24.7M from Dec 31, 2021.
- Collaboration revenue fell to $1.3M (Q3 2022) from $20.9M (Q3 2021) on no GSK milestones.
- Rosnilimab Phase 2 alopecia areata top-line data expected Q1 2023; ANB032 IND Q4 2022.
- Zejula royalty sale to DRI for up to $45M ($35M upfront); GSK earned $5M milestone for cobolimab Phase 3.

## SEC filing metadata
- accession: 0001370053-22-000064
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005322000064/0001370053-22-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005322000064/anab-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-22-000064
- JSON: https://secwatch.observer/filing/0001370053-22-000064.json
- Plain text: https://secwatch.observer/filing/0001370053-22-000064.txt

## Key facts
- Earnings Releases
  ANAPTYSBIO, INC reported financial results for three and nine months ended September 30, 2022.
  - Period: three and nine months ended September 30, 2022
  - Result: reported results
  source text: On November 8, 2022, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1370053/000137005322000064/0001370053-22-000064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.